Spyre Therapeutics
SYRE
80.85
+0.74
+0.92%
Spyre Therapeutics
US · SYRE
#1646 by market cap
Listed 1970
80.85
+0.74
+0.92%
Live - 5344 symbols - heartbeat 10s ago
· 2026-10-08 07:00
Pre-market
80.50
-0.43%
After-hours
81.22
+0.46%
Overnight
79.62
-1.52%
- Market cap
- 7.13B
- P/E (TTM)i
- -40.83
- P/Bi
- 7.47
- EPSi
- -1.98
- Div yieldi
- 0.00%
- 52W posi
- 68%
Reader sentiment
Are you bullish or bearish on SYRE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 8 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.9 percentage points.
Institutional ownership
- Held by institutions
- 110.86% +0.91pp
- Institutions
- 333 +8
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund71.78%
Hedge Fund22.21%
VC/PE Fund11.75%
Individual/Insider5.70%
Public Company4.02%
Private Company0.56%
Government Pension Fund0.31%
Insurance Company0.20%
Top holders as of 2026-06-30
FMR
14.77% · 13.03M sh
BlackRock
7.38% · 6.51M sh
Paradigm Biocapital Advisors LP
5.06% · 4.46M sh
Perceptive Advisors LLC
4.90% · 4.32M sh
RTW Investments, LP
4.82% · 4.25M sh
Vanguard Capital Management, LLC
4.54% · 4.00M sh
Peter Deutsch
4.03% · 3.55M sh
Capital Research
3.71% · 3.27M sh
State Street Global Advisors
3.47% · 3.06M sh
VR Management, LLC
3.39% · 2.99M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 13 buys · 37 sells
| Name | Role | Stake |
|---|---|---|
| Cameron Turtle | COO & Principal Executive Officer | 0.61% |
| Tomas Kiselak | Director | 0.46% |
| Peter Harwin | Director | 0.46% |
| Michael Henderson | Director | 0.08% |
| Scott Burrows | Chief Financial Officer | 0.05% |
| Jeffrey Albers | Director | 0.01% |
| Heidy King-Jones | Chief Legal Officer | 0.00% |
| Mark McKenna | Independent Director | -- |
| Laurie Stelzer | Director | -- |
| Fairmount Funds Management LLC | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Cameron Turtle | COO & Principal Executive Officer | Automatic Disposition | -15,000 | $89.14–93.91 |
| 2026-09-30 | Heidy King-Jones | Chief Legal Officer | Derivative Exercise and Sale | -28,933 | $14.50–93.46 |
| 2026-09-30 | Scott Burrows | Chief Financial Officer | Derivative Exercise and Sale | -25,000 | $14.50–93.57 |
| 2026-09-29 | Scott Burrows | Chief Financial Officer | Intent to Sell (Form 144) | -17,500 | $89.89 |
| 2026-09-01 | Heidy King-Jones | Chief Legal Officer | Derivative Exercise and Sale | -28,399 | $14.50–90.00 |
| 2026-09-01 | Scott Burrows | Chief Financial Officer | Open Market Disposition | -18,232 | $89.35 |
| 2026-08-31 | Cameron Turtle | COO & Principal Executive Officer | Automatic Disposition | -15,000 | $86.36–89.07 |
| 2026-08-31 | Heidy King-Jones | Chief Legal Officer | Intent to Sell (Form 144) | -46,665 | $89.33 |
| 2026-08-31 | Scott Burrows | Chief Financial Officer | Derivative Exercise and Sale | -7,500 | $14.50–89.04 |
| 2026-08-06 | Jeffrey Albers | Director | Automatic Disposition | -18,000 | $104.38–104.68 |
| 2026-08-06 | Jeffrey Albers | Director | Derivative Exercise and Sale | -5,000 | $10.39–104.47 |
| 2026-08-02 | Cameron Turtle | COO & Principal Executive Officer | Automatic Disposition | -15,000 | $93.97–97.46 |
| 2026-08-02 | Scott Burrows | Chief Financial Officer | Derivative Exercise and Sale | -7,500 | $14.50–97.10 |
| 2026-06-30 | Cameron Turtle | COO & Principal Executive Officer | Automatic Disposition | -15,000 | $87.44–88.91 |
| 2026-06-30 | Scott Burrows | Chief Financial Officer | Derivative Exercise and Sale | -7,500 | $14.50–88.37 |
| 2026-06-30 | Sheldon Sloan | Chief Medical Officer | Derivative Exercise and Sale | -8,334 | $27.46–88.34 |
| 2026-06-24 | Scott Burrows | Chief Financial Officer | Derivative Exercise and Sale | -15,000 | $14.50–87.14 |
| 2026-06-22 | Fairmount Funds Management LLC | -- | Private Disposition | -4,018,101 | $85.31 |
| 2026-06-22 | Fairmount Funds Management LLC | -- | Derivative Exercise and Sale | -666,680 | $85.31 |
| 2026-06-21 | Michael Henderson | Director | Automatic Disposition | -20,000 | $100.00 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:00:13 · For reference only, not investment advice and not tailored to your situation.